SCHEMBL2547348

SCHEMBL2547348

CON(C)C(=O)COC1CN(C(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
POLB P06746 1/20 0.44
CACNA2D1 P54289 4/20 0.41
CACNB1 Q02641 4/20 0.41
CACNA1B Q00975 3/20 0.41
CACNA1C Q13936 3/20 0.41
SLC6A9 P48067 1/20 0.41
OPRD1 P41143 1/20 0.41
CYP3A4 P08684 3/20 0.41
CYP2D6 P10635 3/20 0.41
USP2 O75604 1/20 0.41
HIF1A Q16665 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
CACNA1A O00555 1/20 0.39
ACHE P22303 1/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15641647 0.81 NPC1 (0.52) KMT2AALDH1A1CACNA2D1CACNB1CACNA1B
SCHEMBL2589044 0.80 CACNA2D1 (0.48) KMT2AALDH1A1CACNA2D1CACNB1CACNA1B
SCHEMBL3295365 0.78 ALDH1A1 (0.43) KMT2AMEN1ALDH1A1POLBCACNA2D1
SCHEMBL2007270 0.76 OPRM1 (0.47) KMT2AMEN1ALDH1A1CACNA2D1CACNB1
SCHEMBL1768996 0.76 ALDH1A1 (0.44) KMT2AALDH1A1SLC6A9OPRD1CYP3A4
SCHEMBL1768925 0.75 KMT2A (0.40) KMT2ASLC6A9OPRD1CYP3A4CYP2D6
SCHEMBL1768927 0.75 KMT2A (0.40) KMT2ASLC6A9OPRD1CYP3A4CYP2D6
SCHEMBL13778877 0.74 ACHE (0.50) KMT2AMEN1ALDH1A1POLBCACNA2D1
SCHEMBL5802065 0.74 OPRM1 (0.49) KMT2AMEN1ALDH1A1POLBSLC6A9
SCHEMBL1768990 0.73 ALDH1A1 (0.41) KMT2AMEN1ALDH1A1SLC6A9OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2563765-B1 BICYCLIC COMPOUND DERIVATIVES AND THEIR USE AS ACC INHIBITORS. TAKEDA PHARMACEUTICAL (JP) 2015-05-27 EP disclosed
US-8703758-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-04-22 US disclosed
EP-2563765-A1 BICYCLIC COMPOUND DERIVATIVES AND THEIR USE AS ACC INHIBITORS. Takeda Pharmaceutical Company Limited (JP) 2013-03-06 EP disclosed
WO-2011136385-A1 BICYCLIC COMPOUND DERIVATIVES AND THEIR USE AS ACC INHIBITORS. TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-03 WO disclosed
US-20110263562-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263562-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB KMT2A 2195/4885MEN1 2882/4885ALDH1A1 583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.